PCRX Q1 2021 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$971M

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$119M+12.6% YoY

Gross Profit

$88M73.7% margin

Operating Income

$19M16.3% margin

Net Income

$10M8.7% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

-9.1%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

-$992,000

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$637M

Stockholders' Equity

$651M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$119M	$106M	+12.6%
Gross Profit	$88M	$76M	+15.4%
Operating Income	$19M	$17M	+13.7%
Net Income	$10M	$8M	+27.1%

Revenue Segments

Product

$119M51%

EXPAREL/bupivacaine liposome injectable suspension

$115M49%